Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib and Envafolimab in Advanced Bone and Soft Tissue Sarcoma
NCT05941325Phase 2Suspended
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib and envafolimab in bone sarcoma and soft tissue sarcoma (STS), sponsored by Shanghai Sixth People's Hospital. Primary endpoint: Progression-Free Survival at 1 year. Started Apr 2023; status: suspended.
02
Drugs
fruquintinibenvafolimab
03
Conditions
bone sarcomasoft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05941325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05941325.